Repligen (NASDAQ:RGEN - Get Free Report) was upgraded by stock analysts at StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Thursday.
Several other equities research analysts have also recently weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a research note on Monday. JPMorgan Chase & Co. lowered their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective on the stock. Evercore ISI assumed coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Finally, Royal Bank of Canada cut their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average price target of $173.25.
View Our Latest Stock Analysis on Repligen
Repligen Stock Performance
Shares of RGEN stock opened at $126.88 on Thursday. The business's 50-day moving average price is $136.21 and its 200-day moving average price is $145.61. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $7.12 billion, a price-to-earnings ratio of -248.78, a PEG ratio of 4.54 and a beta of 1.21.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company's revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 EPS. Equities research analysts forecast that Repligen will post 1.72 EPS for the current year.
Insider Activity
In other Repligen news, Director Margaret Pax purchased 250 shares of the firm's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company's stock.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Signaturefd LLC lifted its position in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen in the fourth quarter valued at approximately $29,000. Raiffeisen Bank International AG purchased a new position in shares of Repligen during the fourth quarter valued at approximately $29,000. Itau Unibanco Holding S.A. bought a new stake in Repligen during the fourth quarter worth $40,000. Finally, UMB Bank n.a. raised its position in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Repligen Company Profile
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
